Clinuvel (ASX:CUV) share price pinches down after Israeli breakthrough

The Clinuvel (ASX: CUV) share price closed lower today after the company announced expansion into Israel. Here are the latest details.

| More on:
sad, unhappy medical worker, medical share price fall, drop, decrease,

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price closed 1.15% lower today at $21.54. The dip came after the company announced that its SCENESSE product had been added to Israel's 'National Health Basket' (NHB) of reimbursable services and products. 

Clinuvel Pharmaceuticals is a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of genetic and vascular disorders. 

The company's main product is SCENESSE (afamelanotide), a drug targeting erythropoietic protoporphyria (EPP).

What's driving the Clinuvel share price?

Earlier today, Clinuvel announced that it had achieved a positive outcome in Israel regarding its SCENESSE treatment. The product, which is already available in the European Union and the United States, will now be commercially prescribed in Israel.

The company noted that Israel's healthcare costs amounted to 7.5% of GDP, and spending on pharmaceutical products equated to 13.1% of all healthcare. 

Clinuvel said while it was compulsory that Israeli residents were provided insurance under the National Health Insurance Law (enacted 1994), most residents also opted for voluntary health insurance options. This was in order to gain benefits including medications not covered by the standard package, and access to faster healthcare and a more comprehensive network of doctors. 

Management comments

Clinuvel's commercial affairs vice president Antonella Colucci welcomed the expansion into Israel, saying:

Our team has been working tirelessly to facilitate accelerated access to SCENESSE treatment for Israeli EPP patients.

We are establishing a foothold and infrastructure in Israel to enable treatment accessing a country where the risk of EPP burns and phototoxicity is high due to the light intensity and sun exposure. Israeli EPP patients have been at heightened risk for decades and had to learn to live a recluse life.

The Clinuvel share price has fallen more than 17% during the past 12 months. 

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 9 January 2025

Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Medical or healthcare workers grasp hands in the universal expression of teamwork
Healthcare Shares

Here's how the ASX 200 market sectors stacked up last week

Healthcare was the strongest sector last week, with market darling Pro Medicus surging yet again.

Read more »

Three happy multi-ethnic business colleagues discuss investment or finance possibilities in an office.
Financial Shares

The IAG share price soared 50% in 2024! Here's how

IAG shares smashed the benchmark returns in 2024. But how?

Read more »

A happy boy with his dad dabs like a hero while his father checks his phone.
Opinions

These ASX shares have a legit shot at doubling in 5 years

I’m bullish about the outlook for these stocks for several reasons.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

These ASX 200 shares could rise 20% to 40%

Analysts think these shares could deliver big returns for investors this year.

Read more »

A rueful woman tucks into a sweet pie as she contemplates a decision with regret.
Share Market News

Here are the top 10 ASX 200 shares today

It was a rough end to the week this Friday for ASX shares...

Read more »

Three rockets heading to space
Record Highs

3 ASX 300 shares smashing new multi-year highs while the market struggles

The broader market is in the red on Friday but these three shares are riding high.

Read more »

A fresh-faced young woman holds an Australian flag aloft above her head as she smiles widely on a beach as though celebrating a national day or event where Australia has been successful.
Opinions

The only Australian stocks I own at the start of 2025

My portfolio has a mix of studs and potential duds...

Read more »

Best Shares

Which ASX 200 large-cap shares outperformed their peers in 2024?

We reveal the 16 best ASX 200 large-cap stocks for share price growth last year.

Read more »